121 related articles for article (PubMed ID: 23595163)
21. Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer.
Suzuki S; Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Asada K; Masuda M; Yamada T; Watanabe H; Suda T
Invest New Drugs; 2016 Aug; 34(4):490-6. PubMed ID: 27279143
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy of S-1 in Advanced Non-small Cell Lung Cancer Patients Treated
with More Than Two Lines of Chemotherapy].
Yin Y; Wu B; Huang Z; Zhuang W; Xu Z; Huang C; Huang Y; Zhang J
Zhongguo Fei Ai Za Zhi; 2018 Jun; 21(6):437-444. PubMed ID: 29945701
[TBL] [Abstract][Full Text] [Related]
23. [Patterns of recurrence in patients with stage pT3N0M0 thoracic esophageal squamous cell carcinoma after two-field esophagectomy].
Wang Y; Wang L; Yang Q; Li J; He M; Yao J; Qi Z; Li B; Qiao X
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):48-54. PubMed ID: 26796807
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
Lee J; Im YH; Cho EY; Hong YS; Lee HR; Kim HS; Kim MJ; Kim K; Kang WK; Park K; Shim YM
Cancer Chemother Pharmacol; 2008 Jun; 62(1):77-84. PubMed ID: 17762932
[TBL] [Abstract][Full Text] [Related]
25. [Two cases of recurrent non-small cell lung cancer successfully treated with S-1 as fifth-line chemotherapy].
Takakuwa O; Oguri T; Sato S; Nakao M; Ohta C; Iwashima Y; Miyazaki M; Maeno K; Kutsuna T; Nakamura A; Ueda R
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1721-4. PubMed ID: 19838034
[TBL] [Abstract][Full Text] [Related]
26. [The effectiveness of S-1 based sequential chemotherapy as second-line treatment for advanced/recurrent gastric cancer].
Sugimoto N; Narahara H; Sakai D; Yamamoto S; Fumoto S; Yagi T; Imamura F; Iishi H; Tatsuta M
Gan To Kagaku Ryoho; 2009 Mar; 36(3):417-24. PubMed ID: 19295265
[TBL] [Abstract][Full Text] [Related]
27. Selection of a patient subgroup with advanced esophageal squamous carcinoma who could benefit from second-line chemotherapy.
Kim ST; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Oncology; 2010; 79(5-6):363-9. PubMed ID: 21430405
[TBL] [Abstract][Full Text] [Related]
28. [Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma].
Zhang XD; Shen L; Li J; Li Y; Li J; Zhang XT; Jin ML
Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):474-7. PubMed ID: 17974288
[TBL] [Abstract][Full Text] [Related]
29. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
30. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
Lee SJ; Kim S; Kim M; Lee J; Park YH; Im YH; Park SH
BMC Cancer; 2015 Oct; 15():693. PubMed ID: 26468007
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer.
Suzuki S; Ishikawa K
J Infect Chemother; 2009 Oct; 15(5):335-9. PubMed ID: 19856075
[TBL] [Abstract][Full Text] [Related]
32. [A case report of S-1 single effective use as third-line chemotherapy and re-challenge in a recurrent squamous cell lung cancer patient].
Hoshino S; Sugano T; Kitamura T; Furukawa M; Aragane K
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1181-4. PubMed ID: 18633258
[TBL] [Abstract][Full Text] [Related]
33. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
[TBL] [Abstract][Full Text] [Related]
34. Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy.
Chi D; Chen B; Guo S; Bai K; Ma H; Hu Y; Li Q; Zhu Y
Aging (Albany NY); 2021 Mar; 13(6):8408-8420. PubMed ID: 33713398
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study.
Dai X; Tao L; Wang J; Wu W; Bian W; Dai X; Chen S
Cancer Med; 2023 Aug; 12(15):16108-16118. PubMed ID: 37325938
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel, nedaplatin, and S-1 (DGS) chemotherapy for advanced esophageal carcinoma: a phase I dose-escalation study.
Tanaka Y; Yoshida K; Osada S; Yamaguchi K; Takahashi T
Anticancer Res; 2011 Dec; 31(12):4589-97. PubMed ID: 22199335
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
38. Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
Winther SB; Zubcevic K; Qvortrup C; Vestermark LW; Jensen HA; Krogh M; Sorbye H; Pfeiffer P;
Acta Oncol; 2016 Jul; 55(7):881-5. PubMed ID: 27181284
[TBL] [Abstract][Full Text] [Related]
39. The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis.
Qin RQ; Wen YS; Wang WP; Xi KX; Yu XY; Zhang LJ
Med Oncol; 2016 Apr; 33(4):31. PubMed ID: 26922662
[TBL] [Abstract][Full Text] [Related]
40. A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma.
Hiramoto S; Kato K; Shoji H; Okita N; Takashima A; Honma Y; Iwasa S; Hamaguchi T; Yamada Y; Shimada Y; Boku N
Int J Clin Oncol; 2018 Jun; 23(3):466-472. PubMed ID: 29353337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
